Knight Therapeutics Inc. (TSE:GUD - Get Free Report) Director Samira Sakhia purchased 20,000 shares of the stock in a transaction dated Monday, November 11th. The shares were purchased at an average price of C$5.15 per share, with a total value of C$103,000.00.
Knight Therapeutics Stock Performance
GUD stock opened at C$5.17 on Tuesday. The company has a 50-day simple moving average of C$5.74 and a 200 day simple moving average of C$5.75. The company has a market capitalization of C$523.26 million, a P/E ratio of -25.85, a PEG ratio of -1,013.50 and a beta of 0.50. The company has a quick ratio of 1.79, a current ratio of 3.41 and a debt-to-equity ratio of 7.62. Knight Therapeutics Inc. has a fifty-two week low of C$4.98 and a fifty-two week high of C$6.23.
Analysts Set New Price Targets
A number of research analysts have issued reports on the stock. Stifel Nicolaus raised shares of Knight Therapeutics from a "hold" rating to a "buy" rating and boosted their target price for the company from C$5.75 to C$6.75 in a research note on Tuesday, August 13th. Stifel Canada raised Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Monday, August 12th.
View Our Latest Stock Report on Knight Therapeutics
Knight Therapeutics Company Profile
(
Get Free Report)
Blackrock’s Sending THIS Crypto Higher on Purpose
From Crypto 101 Media | Ad
It's a groundbreaking opportunity that could be poised for extraordinary gains.
The catalyst behind this surge is a massive new blockchain development…
YES, I WANT THE #1 CRYPTO NOW
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
